Today's most important initiations

Morgan Stanley initiated coverage on Rocket Pharmaceuticals (NASDAQ: RCKT) with an Overweight rating and a price target of $45.00 as the leader in the gene therapy prepares to enter a pivotal study in Q2/23 with its RP-A501, the first and best-in-class treatment for Danon disease.

BofA Securities initiated coverage on New Fortress Energy (NASDAQ: NFE) with a Buy rating and a price target of $67.00. Shares gained more than 4% today.

Mizuho Securities initiated coverage on General Mills (NYSE: GIS) with a Neutral rating and a price target of $75.00.

Cantor Fitzgerald initiated coverage on Beam Therapeutics Inc (NASDAQ: BEAM) with an Overweight rating and a price target of $62.00. Shares surged more than 5% today.

Raymond James initiated coverage on Everest Re Group (NYSE: RE) with an Outperform rating and a price target of $385.00.

Raymond James initiated coverage on Accolade Inc. (NASDAQ: ACCD) with an Outperform rating and a price target of $15.00.

By Davit Kirakosyan

Want this type of news in real-time as it happens? Upgrade to StreetInsider.com Premium Here

You May Also Be Interested In

• Morgan Stanley Private Credit Fund Caps Redemptions At 5%
• Cantor Fitzgerald Starts Factorial Energy (FAC) at Overweight
• Raymond James Downgrades V2X, Inc. (VVX) to Market Perform